# Acurx Pharmaceuticals, Inc.: overview ACXP · Nasdaq · CIK 1736243 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/acxp.md) · [Financials](/companies/acxp/financials.md) · [Filings](/companies/acxp/filings.md) · [Insiders](/companies/acxp/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(3.45)](/filings/0001104659-25-109698.md) | not reported | [(2.15)](/filings/0001104659-26-058631.md) | [(1.89)](/filings/0001104659-26-095904.md) | [(1.23)](/filings/0001104659-25-109698.md) | not reported | [(0.62)](/filings/0001104659-26-058631.md) | [(0.53)](/filings/0001104659-26-095904.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.49)](/filings/0001558370-23-003929.md) | [(1.12)](/filings/0001558370-24-003401.md) | [(1.15)](/filings/0001558370-25-003117.md) | [(17.45)](/filings/0001104659-26-027052.md) | [(5.32)](/filings/0001104659-26-027052.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/acxp/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $48.2k | 31,099 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $40.9k | 26,411 | | Added +1,592 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $25.1k | 16,205 | | Unchanged | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $24.4k | 15,727 | | Reduced −38,915 | | [Prospect Financial Services LLC](/funds/2012519.md) | 2026-06-30 | $21.4k | 13,785 | | Unchanged | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $11.6k | 7,500 | | Added +1,000 | | [Integrated Wealth Concepts LLC](/funds/1737109.md) | 2026-06-30 | $7.3k | 4,729 | | New +4,729 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $4.3k | 2,744 | | Added +1,713 | | [WELLS FARGO & COMPANY/MN](/funds/72971.md) | 2026-06-30 | $3.6k | 2,300 | | Unchanged | | [Westside Investment Management, Inc.](/funds/1538383.md) | 2026-06-30 | $2.6k | 1,650 | | Unchanged | ## Recent filings [All 245 filings](/companies/acxp/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-29 | 17:20 ET | [8-K](/filings/0001104659-26-120279.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001104659-26-120279 | | 2026-10-16 | 16:30 ET | [8-K](/filings/0001104659-26-116632.md) | 5.07 Shareholder vote results | 0001104659-26-116632 | | 2026-09-08 | 16:27 ET | [S-1](/filings/0001104659-26-105917.md) | Registration statement | 0001104659-26-105917 | | 2026-09-01 | 16:15 ET | [DEF 14A](/filings/0001104659-26-104316.md) | Proxy statement, period 2026-10-16 | 0001104659-26-104316 | | 2026-08-13 | 16:07 ET | [10-Q](/filings/0001104659-26-095904.md) | Quarterly report, period 2026-06-30 | 0001104659-26-095904 | | 2026-05-11 | 16:05 ET | [10-Q](/filings/0001104659-26-058631.md) | Quarterly report, period 2026-03-31 | 0001104659-26-058631 | | 2026-05-04 | 16:09 ET | [S-1](/filings/0001104659-26-054887.md) | Registration statement | 0001104659-26-054887 | | 2026-05-04 | 16:08 ET | [S-1](/filings/0001104659-26-054884.md) | Registration statement | 0001104659-26-054884 | | 2026-04-16 | 08:14 ET | [8-K](/filings/0001104659-26-044093.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-044093 | | 2026-03-12 | 16:06 ET | [10-K](/filings/0001104659-26-027052.md) | Annual report, period 2025-12-31 | 0001104659-26-027052 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-027052.md), filed Mar 12, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1736243 - Tickers: ACXP - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 17:22 ET. No prices; not investment advice.